Theseus Pharmaceuticals, Inc. Common Stock
THRX
THRX was delisted on the 13th of February, 2024.
69 hedge funds and large institutions have $374M invested in Theseus Pharmaceuticals, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 13 reducing their positions, and 13 closing their positions.
108% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 13
7% more capital invested
Capital invested by funds: $351M → $374M (+$23M)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
4% less funds holding
Funds holding: 72 → 69 (-3)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$13.8M |
| 2 |
BlackRock
New York
|
+$4.44M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$4.39M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$2.73M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$1.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$16.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.04M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.73M |
| 4 |
Walleye Capital
New York
|
-$1.59M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$1.28M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SSA
76
Schonfeld Strategic Advisors
New York
| – | -$696K | -78,369 | Closed |
|
|
CSS
77
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$161K | -18,081 | Closed |
|
|
GCP
78
GSA Capital Partners
London,
United Kingdom
| – | -$156K | -17,543 | Closed |
|
|
JF
79
Jump Financial
Chicago,
Illinois
| – | -$141K | -15,859 | Closed |
|
80
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$15K | -1,660 | Closed |
|
|
PVH
81
Psagot Value Holdings
Tel Aviv,
Israel
| – | -$2K | -274 | Closed |
|
|
PMEF
82
Point72 Middle East FZE
Dubai,
United Arab Emirates
| – | -$142 | -16 | Closed |
|
THRX Hedge Fund Activity: Q2 2023 in Review
69 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Theseus Pharmaceuticals, Inc. Common Stock (THRX) for Q2 2023, worth a combined $374M — up 6.6% from $351M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of THRX and 10 opened new positions — a net loss of 3 holders — while 13 trimmed existing stakes and 27 added.
The largest buyer was Deerfield Management, opening a new position worth an estimated $13.8M. The largest seller was Fairmount Funds Management, exiting entirely with an estimated $16.6M sold.
- 69 institutional investors held Theseus Pharmaceuticals, Inc. Common Stock (THRX) as of Q2 2023, down from 72 in Q1 2023.
- Funds reported $374M of Theseus Pharmaceuticals, Inc. Common Stock stock for Q2 2023, up 6.6% quarter-over-quarter.
- 10 funds opened new Theseus Pharmaceuticals, Inc. Common Stock positions in Q2 2023 and 13 closed out, a net change of -3 holders.
- The largest Theseus Pharmaceuticals, Inc. Common Stock buyer in Q2 2023 was Deerfield Management, an estimated $13.8M added.
- The largest Theseus Pharmaceuticals, Inc. Common Stock seller in Q2 2023 was Fairmount Funds Management, an estimated $16.6M sold.
Based on aggregated 13F filings for Q2 2023.